26.11.2014 • TopicsCMI 11-12/2014

Edison in the Boardroom Revisited

Edison in the Boardroom Revisited
Edison in the Boardroom Revisited

This revised and expanded edition of the groundbreaking Edison in the Boardroom, highlights the winning strategies today's biggest companies use to maximize the value of their intellectual property.
The second edition takes an in-depth look at the revolutionary concept of intellectual asset management (IAM). Incorporating stories and teachings from some of the most successful companies in the world-such as Hewlett-Packard, IBM, Procter & Gamble, Rockwell, Dow, Ford and many others-Harrison and Sullivan have made an exhaustive study of IAM and its implications for today's businesses. The book compiles a wealth of knowledge and successful stories that illustrate how far businesses have come in their ability to leverage and monetize their intellectual assets.

Edison in the Boardroom Revisited
Suzanne S. Harrison, Patrick H. Sullivan
John Wiley & Sons
Price: 43.90 Euro
ISBN: 978-1-118-00453-1

 

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
19.03.2025 • TopicsStrategy

The Future of Demand for Chemicals

The chemical industry is shifting to sustainability-related products, with demand growing 4.5 times faster than conventional ones. Companies must revise their market strategies to capitalize on this opportunity.

Photo
14.05.2025 • TopicsPharma

Pharma Outlook 2025

The environment for pharma in 2025 is diverse and challenging: New treatment options are being brought to market in ever shorter cycles.